N/A
Main Article Content
Keywords
Thromboprophylaxis, Anticoagulation, COVID-19
Abstract
The life of the world changed as we knew it, since december 2019, due to a new viral pandemic, the “Coronavirus 2”. Virus of high contagiousness and severity due to Severe Acute Respiratory Syndrome (SARS CoV-2) causing high morbidi- ty and mortality, overwhelmed the Intensive Care Units of the world, to care for these patients whose primarily respiratory symptoms. Currently, it also faces a second threat, the substantial increase compared to other hospitalized patients (not COVID-19) of thromboembolic complications.
This publication aims to review the updated information available regarding the epidemiology, pathophysiology, and management of thromboembolic disease in hospitalized COVID-19 patients.
